Glaukos Co. (NYSE:GKOS) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Glaukos Co. (NYSE:GKOS) by 2.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,542 shares of the medical instruments supplier’s stock after acquiring an additional 610 shares during the period. Mirae Asset Global Investments Co. Ltd. owned approximately 0.05% of Glaukos worth $1,951,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of GKOS. Bank of New York Mellon Corp grew its holdings in Glaukos by 0.6% during the first quarter. Bank of New York Mellon Corp now owns 481,228 shares of the medical instruments supplier’s stock worth $27,825,000 after acquiring an additional 2,843 shares during the period. HighTower Advisors LLC purchased a new position in Glaukos in the 1st quarter worth about $208,000. Natixis Advisors L.P. purchased a new position in Glaukos in the 1st quarter worth about $674,000. Bank of Montreal Can increased its stake in Glaukos by 14.2% in the 1st quarter. Bank of Montreal Can now owns 20,031 shares of the medical instruments supplier’s stock worth $1,164,000 after purchasing an additional 2,485 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in Glaukos by 54.8% in the 1st quarter. MetLife Investment Management LLC now owns 25,057 shares of the medical instruments supplier’s stock worth $1,449,000 after purchasing an additional 8,866 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Stock Up 1.3 %

Shares of Glaukos stock opened at $96.40 on Friday. The stock has a 50-day simple moving average of $91.88 and a 200-day simple moving average of $80.73. Glaukos Co. has a 52-week low of $45.38 and a 52-week high of $102.33. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.34 and a quick ratio of 4.78. The firm has a market cap of $4.84 billion, a price-to-earnings ratio of -34.68 and a beta of 1.08.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.07). Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The company had revenue of $82.40 million during the quarter, compared to analyst estimates of $81.00 million. During the same quarter last year, the firm posted ($0.53) earnings per share. The firm’s revenue for the quarter was up 15.7% compared to the same quarter last year. On average, equities research analysts expect that Glaukos Co. will post -2.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on GKOS. Truist Financial reissued a “buy” rating and issued a $110.00 price target on shares of Glaukos in a research note on Monday, April 8th. Needham & Company LLC lifted their price target on Glaukos from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Stifel Nicolaus reaffirmed a “buy” rating and set a $110.00 target price on shares of Glaukos in a research note on Wednesday, April 3rd. Wells Fargo & Company lifted their target price on Glaukos from $83.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, February 22nd. Finally, StockNews.com cut Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $99.80.

Insider Buying and Selling

In related news, COO Joseph E. Gilliam sold 59,801 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $100.47, for a total value of $6,008,206.47. Following the completion of the sale, the chief operating officer now directly owns 101,845 shares in the company, valued at approximately $10,232,367.15. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, COO Joseph E. Gilliam sold 59,801 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $100.47, for a total value of $6,008,206.47. Following the completion of the sale, the chief operating officer now directly owns 101,845 shares in the company, valued at approximately $10,232,367.15. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Alex R. Thurman sold 474 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $90.37, for a total value of $42,835.38. Following the completion of the sale, the chief financial officer now owns 54,916 shares of the company’s stock, valued at $4,962,758.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 242,881 shares of company stock worth $22,906,633. 7.80% of the stock is currently owned by insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.